Another retrospective cohort study, which included 543,595 diabetic patients, found no increased risk of pancreatic cancer associated with GLP-1RA use compared to basal insulin over a 9-year follow-up period (Dankner et al., 2024). The gene discussed is INS; the disease is pancreatic neoplasm.